DE
skin cancer
Skin Cancer
As the incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades, better treatment modalities are needed.
read more
vda-1102
VDA-1102
VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.
read more
technology spotlight
Technology Spotlight
HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.
read more
skin cancer
Skin Cancer
As the incidence of both non-melanoma and melanoma skin cancers has been increasing over the past decades, better treatment modalities are needed.
read more
vda-1102
VDA-1102
VDA-1102 ointment is the FIRST in a new class of drugs that selectively targets malignant skin cancer cells with minimal effects on surrounding healthy skin.
read more
technology spotlight
Technology Spotlight
HK2 has a vital role in cancer metabolism. Vidac is creating innovative therapies for people suffering from a range of oncology and dermatology ailments.
read more

Science: HK2 - A Major Driver of Cancer

cancerdriver

VDA-1102 VDAC/HK2 MOA

HKS N-terminal-helix flips out of place to allow VDAC's N-terminal-helix to replace it, thus binding the two proteins.
cancerdriver

VDA-1102 Inhibits Cancer Proliferation

VDA-1102 demonstrated strong inhibition of cancer growth across multiple indications.

70% of a panel with 57 cancer models (2019-2021)

Threshold <2uM; Colony forming assay in 57 patient-derived tumors and cancer cell lines conducted at Oncotest GmbH, a division of Charles River Labs.

Pipeline

Vidac has built a portfolio of novel product candidates that target significant unmet medical needs in oncology and dermatology.

read more

Therapeutic Areas

Vidac is creating innovative therapies for people suffering from a range of oncologic and dermatologic medical conditions.

read more